Loading...
Loading...
will miss quarterly sales expectations for its Tecfidera treatment for multiple sclerosis Friday but the disappointment shouldn't roil the company's shares, an analyst said this week.
Morgan Stanley's Matthew Harrison said Biogen in the past has proven volatile after missing Tecfidera expectations.
But Harrison said a promising outlook for Biogen's proposed Alzheimer's treatment BIIB037 "provides a new floor" that could dampen volatility.
Harrison expects Biogen's overall results will meet Wall Street consensus of $3.91 a share on revenue of $2.66 billion.
But Tecfidera sales of $890 million will miss consensus expectations by about 2 percent, according to his estimate.
Separately, Harrison said
Gilead Sciences, Inc.GILD's Harvoni treatment for hepatitis C doesn't appear threatened by recent drug trial data from
Merck & Co., Inc.MRK.
Results from Merck's study of its grazoprevir/elbasvir hepatitis drug "continue to position Harvoni as first-in-class."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in